published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsVERU-111, 2022 0.30 [0.14; 0.64] 0.30[0.14; 0.64]VERU-111, 202210%150NAnot evaluable death D28detailed resultsCAN-COVID, 2020 0.67 [0.30; 1.50] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] CORIMUNO-ANA-1, 2021 0.91 [0.38; 2.19] FACCT Trial, 2021 0.69 [0.28; 1.68] GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] I-TECH (Lim), 2022 0.31 [0.09; 1.09] Krolewiecki, 2020 0.49 [0.01; 26.05] Pandit, 2021 0.95 [0.02; 50.33] RAPID (Sholzberg), 2021 0.22 [0.07; 0.67] Shashi Bhushan, 2021 4.39 [0.20; 98.33] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] 0.60[0.45; 0.79]CAN-COVID, 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Krolewiecki, 2020, Pandit, 2021, RAPID (Sholzberg), 2021, Shashi Bhushan, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021120%4,186moderatelow death or transfer to ICUdetailed resultsRAPID (Sholzberg), 2021 0.70 [0.44; 1.12] 0.70[0.44; 1.12]RAPID (Sholzberg), 202110%465NAnot evaluable deathsdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20] CAN-COVID, 2020 0.67 [0.30; 1.50] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] CORIMUNO-ANA-1, 2021 0.97 [0.46; 2.04] Dabbous HM, 2020 0.51 [0.02; 15.41] FACCT Trial, 2021 0.96 [0.44; 2.08] Fu, 2020 1.00 [0.02; 51.66] GS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] Hung et al., 2020 0.47 [0.01; 24.30] I-TECH (Lim), 2022 0.31 [0.09; 1.09] Khamis, 2020 0.83 [0.23; 2.96] Kirti, 2021 0.12 [0.01; 2.36] Krolewiecki, 2020 0.49 [0.01; 26.05] Libster, 2020 0.50 [0.09; 2.71] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] Lopes (BRACE CORONA), 2021 0.97 [0.38; 2.50] NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25] NCT04542694, 2020 1.00 [0.02; 50.90] Pandit, 2021 0.95 [0.02; 50.33] RAPID (Sholzberg), 2021 0.22 [0.07; 0.67] Ren, 2020 1.00 [0.02; 55.80] SAVE-MORE, 2021 0.45 [0.20; 0.99] Shashi Bhushan, 2021 4.39 [0.20; 98.33] Solaymani-Dodaran, 2021 1.22 [0.66; 2.26] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.61 [0.41; 0.92] Udwadia, 2020 0.50 [0.02; 15.03] 0.74[0.63; 0.87]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, CAN-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, Dabbous HM, 2020, FACCT Trial, 2021, Fu, 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Krolewiecki, 2020, Libster, 2020, LIVE-AIR (Temesgen), 2021, Lopes (BRACE CORONA), 2021, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, RAPID (Sholzberg), 2021, Ren, 2020, SAVE-MORE, 2021, Shashi Bhushan, 2021, Solaymani-Dodaran, 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Udwadia, 2020310%11,334moderatecritical deaths (time to event analysis only)detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] 0.68[0.43; 1.08]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, LIVE-AIR (Temesgen), 202140%1,620moderatenot evaluable clinical deteriorationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12] COL-COVID (Pascual-Figal), 2021 0.38 [0.09; 1.58] CORIMUNO-ANA-1, 2021 0.89 [0.42; 1.92] ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57] ELACOI (Standard of care), 2020 0.86 [0.06; 11.36] I-TECH (Lim), 2022 1.25 [0.87; 1.80] Li T, 2020 0.48 [0.01; 27.44] Libster, 2020 0.52 [0.29; 0.94] NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84] RAPID (Sholzberg), 2021 0.69 [0.43; 1.10] Ravichandran, 2021 0.02 [0.00; 0.36] SAVE-MORE, 2021 0.36 [0.26; 0.50] 0.69[0.47; 1.00]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COL-COVID (Pascual-Figal), 2021, CORIMUNO-ANA-1, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, I-TECH (Lim), 2022, Li T, 2020, Libster, 2020, NCT04523831 (Mahmud), 2020, RAPID (Sholzberg), 2021, Ravichandran, 2021, SAVE-MORE, 20211372%2,750moderatelow clinical improvementdetailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] CAN-COVID, 2020 1.39 [0.76; 2.54] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] Ghandehari, 2020 1.31 [1.00; 1.71] GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02] GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] Hung et al., 2020 3.92 [1.66; 9.24] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] NCT04542694, 2020 2.10 [1.04; 4.24] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Shashi Bhushan, 2021 0.68 [0.21; 2.20] Udwadia, 2020 1.75 [1.10; 2.79] 1.30[1.04; 1.62]AVIFAVIR, 2020, CAN-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, Ghandehari, 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Udwadia, 20201466%3,803moderatelow clinical improvement (14-day)detailed resultsAVIFAVIR, 2020 0.53 [0.13; 2.19] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43] GS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29] GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] Pandit, 2021 8.77 [0.94; 81.67] Ruzhentsova T, 2020 1.28 [1.05; 1.56] Shashi Bhushan, 2021 0.68 [0.21; 2.20] 1.22[1.00; 1.49]AVIFAVIR, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 20211032%2,913moderatelow clinical improvement (21-day)detailed resultsLi T, 2020 2.09 [0.04; 119.96] 2.09[0.04; 119.96]Li T, 202010%18NAnot evaluable clinical improvement (28-day)detailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57] GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] Ruzhentsova T, 2020 1.11 [0.96; 1.29] Udwadia, 2020 1.75 [1.10; 2.79] 1.34[1.10; 1.62]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020, Udwadia, 2020546%3,321moderateserious clinical improvement (7-day)detailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35] GS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23] GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09] Kirti, 2021 0.90 [0.77; 1.06] NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93] NCT04542694, 2020 2.10 [1.04; 4.24] Ruzhentsova T, 2020 1.50 [1.02; 2.21] Shashi Bhushan, 2021 1.91 [1.03; 3.53] 1.32[1.05; 1.67]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kirti, 2021, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021969%2,577moderateserious clinical improvement (time to event analysis only)detailed resultsFACCT Trial, 2021 0.85 [0.62; 1.16] GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02] GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44] GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42] Hung et al., 2020 3.92 [1.66; 9.24] NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38] Ruzhentsova T, 2020 1.63 [1.14; 2.34] Shinkai, 2021 1.40 [0.91; 2.15] Solaymani-Dodaran, 2021 0.94 [0.75; 1.17] Udwadia, 2020 1.75 [1.10; 2.79] 1.22[1.01; 1.49]FACCT Trial, 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, NCT04523831 (Mahmud), 2020, Ruzhentsova T, 2020, Shinkai, 2021, Solaymani-Dodaran, 2021, Udwadia, 20201073%2,828moderatecritical death or ventilationdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07] CORIMUNO-ANA-1, 2021 0.97 [0.62; 1.52] LIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98] RAPID (Sholzberg), 2021 0.59 [0.34; 1.02] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 0.66 [0.46; 0.94] 0.75[0.63; 0.88]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021, CORIMUNO-ANA-1, 2021, LIVE-AIR (Temesgen), 2021, RAPID (Sholzberg), 2021, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 202150%4,009moderatenot evaluable hospital dischargedetailed resultsFACCT Trial, 2021 0.88 [0.64; 1.21] Kirti, 2021 1.20 [0.73; 1.98] Li T, 2020 10.00 [1.03; 97.50] Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 1.48 [1.05; 2.09] Udwadia, 2020 1.41 [0.97; 2.03] 1.25[0.92; 1.70]FACCT Trial, 2021, Kirti, 2021, Li T, 2020, Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021, Udwadia, 2020556%1,731moderatenot evaluable hospitalizationdetailed resultsJagannathan, 2020 1.00 [0.14; 7.34] 1.00[0.14; 7.34]Jagannathan, 202010%120NAnot evaluable mechanical ventilationdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30] GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45] I-TECH (Lim), 2022 0.41 [0.13; 1.30] Kirti, 2021 0.20 [0.00; 8.69] Li T, 2020 0.40 [0.04; 3.90] Lopes (BRACE CORONA), 2021 1.25 [0.76; 2.06] RAPID (Sholzberg), 2021 0.70 [0.32; 1.54] SAVE-MORE, 2021 0.47 [0.03; 7.48] Solaymani-Dodaran, 2021 1.62 [0.85; 3.08] Udwadia, 2020 0.06 [0.01; 0.83] 0.90[0.59; 1.37]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Kirti, 2021, Li T, 2020, Lopes (BRACE CORONA), 2021, RAPID (Sholzberg), 2021, SAVE-MORE, 2021, Solaymani-Dodaran, 2021, Udwadia, 20201337%4,288moderatecritical mechanical ventilation (time to event analysis only)detailed resultsUdwadia, 2020 0.06 [0.01; 0.83] 0.06[0.01; 0.83]Udwadia, 202010%14NAnot evaluable radiologic improvement (14-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28] ELACOI (Standard of care), 2020 0.18 [0.01; 3.99] Rashad (CLARI vs SoC), 2021 2.87 [1.56; 5.28] Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88] 1.82[0.95; 3.51]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Rashad (CLARI vs SoC), 2021, Rashad A (AZI vs SoC), 2021439%450moderatenot evaluable radiologic improvement (7-day)detailed resultsELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09] ELACOI (Standard of care), 2020 0.08 [0.00; 1.71] Ren, 2020 19.00 [0.85; 422.73] 0.53[0.02; 17.19]ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Ren, 2020374%66moderatenot evaluable viral clearance detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Chaccour, 2020 0.92 [0.77; 1.09] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] Hung et al., 2020 4.37 [1.86; 10.25] Jagannathan, 2020 0.81 [0.56; 1.18] NCT04542694, 2020 13.03 [2.96; 57.24] Pandit, 2021 2.33 [0.55; 9.83] Ravichandran, 2021 1.71 [0.80; 3.64] Ren, 2020 28.50 [1.27; 640.66] Ruzhentsova T, 2020 1.28 [0.92; 1.79] Shashi Bhushan, 2021 2.77 [1.44; 5.32] Udwadia, 2020 1.37 [0.94; 1.98] 1.74[1.25; 2.42]AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Hung et al., 2020, Jagannathan, 2020, NCT04542694, 2020, Pandit, 2021, Ravichandran, 2021, Ren, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 2021, Udwadia, 20201473%1,422moderatecritical viral clearance (time to event analysis only)detailed resultsHung et al., 2020 4.37 [1.86; 10.25] Jagannathan, 2020 0.81 [0.56; 1.18] Ruzhentsova T, 2020 1.28 [0.92; 1.79] Udwadia, 2020 1.37 [0.94; 1.98] 1.39[0.88; 2.20]Hung et al., 2020, Jagannathan, 2020, Ruzhentsova T, 2020, Udwadia, 2020478%565moderatenot evaluable viral clearance by day 14detailed resultsAVIFAVIR, 2020 3.08 [0.62; 15.39] ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38] ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76] ELACOI (Standard of care), 2020 2.80 [0.31; 25.53] Li T, 2020 1.00 [0.03; 34.67] Pandit, 2021 10.23 [1.12; 93.35] Ruzhentsova T, 2020 0.99 [0.93; 1.06] Shashi Bhushan, 2021 0.00 [0.00; 0.01] 0.89[0.14; 5.54]AVIFAVIR, 2020, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Li T, 2020, Pandit, 2021, Ruzhentsova T, 2020, Shashi Bhushan, 2021894%1,725moderatenot evaluable viral clearance by day 7detailed resultsAVIFAVIR, 2020 3.89 [1.23; 12.29] Chaccour, 2020 0.92 [0.77; 1.09] Dabbous HM, 2020 1.33 [0.60; 2.93] ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89] ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91] ELACOI (Standard of care), 2020 0.67 [0.10; 4.58] Kirti, 2021 0.80 [0.43; 1.50] Pandit, 2021 2.33 [0.55; 9.83] Ravichandran, 2021 1.71 [0.80; 3.64] Ren, 2020 28.50 [1.27; 640.66] Ruzhentsova T, 2020 1.05 [0.92; 1.20] Shashi Bhushan, 2021 2.77 [1.44; 5.32] 1.24[0.96; 1.61]AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirti, 2021, Pandit, 2021, Ravichandran, 2021, Ren, 2020, Ruzhentsova T, 2020, Shashi Bhushan, 20211257%1,006moderatelow ICU admissiondetailed resultsCOL-COVID (Pascual-Figal), 2021 0.47 [0.08; 2.69] FACCT Trial, 2021 1.42 [0.79; 2.55] I-TECH (Lim), 2022 0.78 [0.27; 2.23] Khamis, 2020 1.03 [0.35; 3.03] Kirti, 2021 0.90 [0.30; 2.70] Libster, 2020 0.33 [0.07; 1.58] RAPID (Sholzberg), 2021 0.79 [0.48; 1.30] Solaymani-Dodaran, 2021 1.23 [0.70; 2.18] 0.98[0.74; 1.29]COL-COVID (Pascual-Figal), 2021, FACCT Trial, 2021, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Libster, 2020, RAPID (Sholzberg), 2021, Solaymani-Dodaran, 202180%2,046moderatenot evaluable recoverydetailed resultsCrippa (CANDIDATE), 2021 0.54 [0.15; 1.94] GS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03] GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37] GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45] 1.01[0.82; 1.25]Crippa (CANDIDATE), 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020456%1,284moderatenot evaluable severe COVID-19 occurrencedetailed resultsELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27] 0.30[0.07; 1.27]ELACOI (Lopinavir/ritonavir), 202010%69NAnot evaluable serious adverse eventsdetailed resultsCAN-COVID, 2020 0.73 [0.45; 1.19] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10] COL-COVID (Pascual-Figal), 2021 0.24 [0.01; 5.41] GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23] GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14] Hung et al., 2020 0.23 [0.01; 7.12] Jagannathan, 2020 1.00 [0.14; 7.34] Krolewiecki, 2020 1.00 [0.03; 31.59] NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58] NCT04542694, 2020 6.15 [0.30; 124.49] Pandit, 2021 0.95 [0.02; 50.33] Ren, 2020 1.00 [0.02; 55.80] Ruzhentsova T, 2020 2.06 [0.09; 46.40] Shinkai, 2021 2.80 [0.14; 56.95] Udwadia, 2020 1.03 [0.02; 52.48] 0.74[0.53; 1.03]CAN-COVID, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, Jagannathan, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Ren, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020160%3,570moderatecritical acute kidney injury detailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18] 1.18[0.44; 3.18]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable adverse eventsdetailed resultsChaccour, 2020 1.00 [0.20; 5.07] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78] COL-COVID (Pascual-Figal), 2021 1.72 [0.73; 4.08] GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42] GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80] Jagannathan, 2020 1.33 [0.63; 2.78] Krolewiecki, 2020 1.53 [0.42; 5.58] NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77] NCT04542694, 2020 1.00 [0.54; 1.85] Pandit, 2021 1.68 [0.47; 5.97] Ravichandran, 2021 1.04 [0.02; 52.86] Ren, 2020 0.12 [0.01; 2.86] Ruzhentsova T, 2020 1.90 [0.96; 3.80] Shinkai, 2021 19.54 [7.77; 49.11] Udwadia, 2020 6.36 [2.43; 16.65] 1.83[1.30; 2.59]Chaccour, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, COL-COVID (Pascual-Figal), 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Jagannathan, 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Pandit, 2021, Ravichandran, 2021, Ren, 2020, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 20201769%3,561moderatelow arrhythmiadetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69] 2.24[0.23; 21.69]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable elevated liver enzymesdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64] 3.48[1.40; 8.64]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%416NAnot evaluable long QTdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50] 9.79[1.27; 75.50]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%174NAnot evaluable Major bleedingdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67] 1.80[0.88; 3.67]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,227NAnot evaluable renal impairmentdetailed resultsCOALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86] 1.35[0.47; 3.86]COALITION I Covid-19 Brazil (AZI, Cavalcanti), 202010%331NAnot evaluable serious adverse events (SAE), anydetailed resultsGS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79] 0.50[0.32; 0.79]GS-US-540-5773 (Goldman), 202010%397NAnot evaluable Thromboembolic eventsdetailed resultsCoalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55] 0.89[0.31; 2.55]Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 202010%345NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-10-31 23:51 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290